Skip to Content

VP-GSTN (cholecalciferol / genistein / zinc glycinate) Disease Interactions

There are 10 disease interactions with VP-GSTN (cholecalciferol / genistein / zinc glycinate):

Major

Genistein (applies to VP-GSTN) breast cancer

Major Potential Hazard, Moderate plausibility. Applicable conditions: Neoplasia -- Estrogen Dependent

The use of genistein is contraindicated in patients with a history of cancer of the breast or reproductive organs and should be used with caution by women who have a history of breast or reproductive cancer in first degree female relatives.

Major

Vitamin D analogs (applies to VP-GSTN) arrhythmia

Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

References

  1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
Major

Vitamin D analogs (applies to VP-GSTN) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
View all 4 references
Major

Vitamin D analogs (applies to VP-GSTN) hypercalcemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

Major

Vitamin D analogs (applies to VP-GSTN) renal dysfunction

Major Potential Hazard, High plausibility.

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
Moderate

Chromium/selenium/zinc (applies to VP-GSTN) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.

References

  1. "Product Information. Chroma-Pak (chromic chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Sele-Pak (selenious acid)." Fujisawa, Deerfield, IL.
  3. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA, North Wales, PA.
Moderate

Genistein (applies to VP-GSTN) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Genistein in the combination product containing genistein, zinc glycinate citrate, and cholecalciferol significantly reduces fasting glucose and insulin levels, as well as insulin resistance. Care should be exercised when using products containing genistein in diabetic patents.

Moderate

Genistein (applies to VP-GSTN) GI malabsorption

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Patients with gastrointestinal malabsorption taking the combination product containing genistein, zinc glycinate citrate, and cholecalciferol may require higher doses of vitamin D3. It is recommended to measure serum levels of 25-hydroxycholecalciferol regularly in this population.

Moderate

Trace metals (applies to VP-GSTN) malabsorption syndromes

Moderate Potential Hazard, Moderate plausibility.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

References

  1. "Product Information. Chroma-Pak (chromic chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA, North Wales, PA.
  3. "Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Sele-Pak (selenious acid)." Fujisawa, Deerfield, IL.
  5. "Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc, Shirley, NY.
  6. "Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group, Texarkana, TX.
View all 6 references
Moderate

Vitamin D analogs (applies to VP-GSTN) hepatobiliary dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease, Biliary Obstruction

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

References

  1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.

VP-GSTN (cholecalciferol / genistein / zinc glycinate) drug interactions

There are 324 drug interactions with VP-GSTN (cholecalciferol / genistein / zinc glycinate)

More about VP-GSTN (cholecalciferol / genistein / zinc glycinate)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.